Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | DNA methyltransferase inhibitors: daratumumab enhancement for MM

Priya Choudhry • 14 Sep 2019
IMW 2019
Multiple Myeloma Antibodies Daratumumab

Priya Choudhry, PhD, from the University of California, San Francisco, CA, discusses how the use of DNA methyltransferase inhibitors upregulate CD38 expression and enhance daratumumab efficacy at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Priya Choudhry

1:09
Daratumumab enhancement for MM: the clinical impact
Priya Choudhry • 14 Sep 2019

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals